Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease
André Malanda,
Pierre-Yves Abécassis,
Pascal Barnéoud,
Pascale Brunel,
Véronique Taupin,
Xavier Vigé,
Dominique Lesuisse
Affiliations
André Malanda
IDD, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France; Corresponding author.
Pierre-Yves Abécassis
DSAR, Sanofi, 13 quai Jules Guesde, F-94403 Vitry-sur-Seine, France
Pascal Barnéoud
Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France
This article describes the chemical synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel Nurr1/NOT agonist. It is meant as a support to an article recently published in Bioorganic and Medicinal chemistry Letters and entitled “Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease” [1] and presenting the discovery, scope and potential of these new ligands of these nuclear receptors.
